SA237 in NMO


This study will evaluate the efficacy and safety of SA237 compared with placebo in subjects with Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD). Males and females age 12-17 years diagnosed with NMO or NMOSD will be eligible to participate. Caregivers will also be asked to complete questionnaires about themselves and will be considered subjects. Procedures include biological specimen collection, radiologic screenings, and questionnaires. The PI for this study is Dr. Sarah Hopkins who can be contacted at 215-590-1719 or IRB 15-012095

For More Information

Contact Us Online

Call (267) 426-6846